LIFE - aTyr Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

aTyr Pharma, Inc.

3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States
858 731 8389

Full Time Employees65

Key Executives

NameTitlePayExercisedYear Born
Dr. Sanjay S. Shukla M.D., M.S.Pres, CEO & Director795.48kN/A1972
Ms. Jill M. BroadfootChief Financial Officer556.62kN/A1962
Ms. Nancy E. Denyes KruegerGen. Counsel & Corp. Sec.532.13kN/A1968
Xiang-Lei Yang Ph.D.FounderN/AN/AN/A
Ms. Ashlee DunstonDirector of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Peter VilligerVP of Corp. Devel.N/AN/AN/A
Ms. Danielle CampbellVP of Human ResourceN/AN/AN/A
Dr. Leslie Nangle Ph.D.VP of ResearchN/AN/AN/A
Dr. Ying J. Buechler Ph.D.Exec. Director of Biologics Devel. & ManufacturingN/AN/AN/A
Dr. David J. KingScientific ConsultantN/AN/A1959
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Corporate Governance

aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.